A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with...
| Autores: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Instituto de Salud Carlos III (ISCIII) |
| Repositorio: | Repisalud |
| Idioma: | inglés |
| OAI Identifier: | oai:repisalud.isciii.es:20.500.12105/18255 |
| Acceso en línea: | http://hdl.handle.net/20.500.12105/18255 |
| Access Level: | acceso abierto |
| Palabra clave: | Trabectedin Sarcoma Growth modulation index Prognostic score L-sarcoma GEISTRA Spain Advanced soft tissue sarcomas Trabectedina Pronóstico Liposarcoma Leiomiosarcoma España Humans Prognosis Retrospective Studies Thiamine Triphosphate Multivariate Analysis Leiomyosarcoma |
| id |
ES_e04065a4ebb7ce237e4625d9cbf8bcbc |
|---|---|
| oai_identifier_str |
oai:repisalud.isciii.es:20.500.12105/18255 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
| title |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
| spellingShingle |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study Martínez-Trufero, Javier Trabectedin Sarcoma Growth modulation index Prognostic score L-sarcoma GEISTRA Spain Advanced soft tissue sarcomas Trabectedina Pronóstico Liposarcoma Leiomiosarcoma España Humans Prognosis Retrospective Studies Thiamine Triphosphate Spain Sarcoma Multivariate Analysis Leiomyosarcoma Liposarcoma |
| title_short |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
| title_full |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
| title_fullStr |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
| title_full_unstemmed |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
| title_sort |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study |
| dc.creator.none.fl_str_mv |
Martínez-Trufero, Javier De Sande-González, Luis Miguel Luna, Pablo Martin-Broto, Javier Álvarez, Rosa Marquina, Gloria Diaz-Beveridge, Roberto Poveda, Andrés Cano, Juana María Cruz-Jurado, Josefina López Pousa, Antonio Vaz Salgado, María Angeles Valverde-Morales, Claudia M. Sevilla, Isabel Martínez-García, Jerónimo Rubio-Casadevall, Jordi De Juan, Ana Carrasco, Juan Antonio Moura, David S. Gurruchaga-Sotes, Ibon Gutiérrez, Antonio |
| author |
Martínez-Trufero, Javier |
| author_facet |
Martínez-Trufero, Javier De Sande-González, Luis Miguel Luna, Pablo Martin-Broto, Javier Álvarez, Rosa Marquina, Gloria Diaz-Beveridge, Roberto Poveda, Andrés Cano, Juana María Cruz-Jurado, Josefina López Pousa, Antonio Vaz Salgado, María Angeles Valverde-Morales, Claudia M. Sevilla, Isabel Martínez-García, Jerónimo Rubio-Casadevall, Jordi De Juan, Ana Carrasco, Juan Antonio Moura, David S. Gurruchaga-Sotes, Ibon Gutiérrez, Antonio |
| author_role |
author |
| author2 |
De Sande-González, Luis Miguel Luna, Pablo Martin-Broto, Javier Álvarez, Rosa Marquina, Gloria Diaz-Beveridge, Roberto Poveda, Andrés Cano, Juana María Cruz-Jurado, Josefina López Pousa, Antonio Vaz Salgado, María Angeles Valverde-Morales, Claudia M. Sevilla, Isabel Martínez-García, Jerónimo Rubio-Casadevall, Jordi De Juan, Ana Carrasco, Juan Antonio Moura, David S. Gurruchaga-Sotes, Ibon Gutiérrez, Antonio |
| author2_role |
author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
[Martínez-Trufero,J; Gurruchaga-Sotes,I] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González,LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna,P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto,J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS; CSIC, US, HUVR), Sevilla, Spain. [Álvarez,R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina,G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Diaz-Beveridge,R] Medical Oncology Department, Hospital Politécnico La Fe, Valencia, Spain. [Poveda,A] Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia, Spain. [Cano,JM] Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. [Cruz-Jurado,J] Medical Oncology Department, Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain. [López Pousa,A] Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. [Vaz Salgado,MA] Medical Oncology Department, Hospital Universitario Ramon y Cajal, RYCIS, CIBERONC, Madrid, Spain. [Valverde-Morales,C] Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain. [Sevilla,I] Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Medical Oncology Department, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain. [Martínez-García,J] Medical Oncology Department, Hospital Virgen de la Arrixaca, Murcia, Spain. [Rubio-Casadevall,J] Medical Oncology Department, Instituto Catalan Oncologia, Girona, Spain. [De Juan,A] Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain. [Carrasco,JA] Medical Oncology Department, Hospital Alvaro Cunqueiro, Vigo, Spain. [Moura,DS] Instituto de Biomedicina de Sevilla (IBiS; CSIC, US, HUVR), Sevilla, Spain. [Gutiérrez,A] Hematology Department, Hospital Universitario Son Espases, 07010 Palma de Mallorca, Spain. |
| dc.subject.none.fl_str_mv |
Trabectedin Sarcoma Growth modulation index Prognostic score L-sarcoma GEISTRA Spain Advanced soft tissue sarcomas Trabectedina Pronóstico Liposarcoma Leiomiosarcoma España Humans Prognosis Retrospective Studies Thiamine Triphosphate Spain Sarcoma Multivariate Analysis Leiomyosarcoma Liposarcoma |
| topic |
Trabectedin Sarcoma Growth modulation index Prognostic score L-sarcoma GEISTRA Spain Advanced soft tissue sarcomas Trabectedina Pronóstico Liposarcoma Leiomiosarcoma España Humans Prognosis Retrospective Studies Thiamine Triphosphate Spain Sarcoma Multivariate Analysis Leiomyosarcoma Liposarcoma |
| description |
The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 2021-02-14 2021 2021-02-14 2024 2024-02-19 |
| dc.type.none.fl_str_mv |
research article http://purl.org/coar/resource_type/c_2df8fbb1 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/20.500.12105/18255 |
| url |
http://hdl.handle.net/20.500.12105/18255 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute (MDPI) |
| publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute (MDPI) |
| dc.source.none.fl_str_mv |
reponame:Repisalud instname:Instituto de Salud Carlos III (ISCIII) |
| instname_str |
Instituto de Salud Carlos III (ISCIII) |
| reponame_str |
Repisalud |
| collection |
Repisalud |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869422185058140160 |
| spelling |
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective StudyMartínez-Trufero, JavierDe Sande-González, Luis MiguelLuna, PabloMartin-Broto, JavierÁlvarez, RosaMarquina, GloriaDiaz-Beveridge, RobertoPoveda, AndrésCano, Juana MaríaCruz-Jurado, JosefinaLópez Pousa, AntonioVaz Salgado, María AngelesValverde-Morales, Claudia M.Sevilla, IsabelMartínez-García, JerónimoRubio-Casadevall, JordiDe Juan, AnaCarrasco, Juan AntonioMoura, David S.Gurruchaga-Sotes, IbonGutiérrez, AntonioTrabectedinSarcomaGrowth modulation indexPrognostic scoreL-sarcomaGEISTRASpainAdvanced soft tissue sarcomasTrabectedinaPronósticoLiposarcomaLeiomiosarcomaEspañaHumansPrognosisRetrospective StudiesThiamine TriphosphateSpainSarcomaMultivariate AnalysisLeiomyosarcomaLiposarcomaThe aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second- or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI > 1.33) were associated with the better clinical outcome. Univariate and multivariate analyses were performed to identify factors associated with a GMI > 1.33. Thus, GEISTRA score was based on metastasis free-interval (MFI ≤ 9.7 months), Karnofsky < 80%, Non L-sarcomas and better response in the previous systemic line. The median GMI was 0.82 (0–69), with 198 patients (55%) with a GMI < 1, 41 (11.5%) with a GMI 1–1.33 and 118 (33.1%) with a GMI > 1.33. The lowest GEISTRA score showed a median of time-to-progression (TTP) and overall survival (OS) of 5.7 and 19.5 months, respectively, whereas it was 1.8 and 3.1 months for TTP and OS, respectively, for the GEISTRA 4 score. This prognostic tool can contribute to better selecting candidates for trabectedin treatment in ASTS.Multidisciplinary Digital Publishing Institute (MDPI)[Martínez-Trufero,J; Gurruchaga-Sotes,I] Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. [De Sande-González,LM] Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. [Luna,P] Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Martin-Broto,J] Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS; CSIC, US, HUVR), Sevilla, Spain. [Álvarez,R] Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. [Marquina,G] Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. [Diaz-Beveridge,R] Medical Oncology Department, Hospital Politécnico La Fe, Valencia, Spain. [Poveda,A] Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia, Spain. [Cano,JM] Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. [Cruz-Jurado,J] Medical Oncology Department, Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain. [López Pousa,A] Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. [Vaz Salgado,MA] Medical Oncology Department, Hospital Universitario Ramon y Cajal, RYCIS, CIBERONC, Madrid, Spain. [Valverde-Morales,C] Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain. [Sevilla,I] Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Medical Oncology Department, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain. [Martínez-García,J] Medical Oncology Department, Hospital Virgen de la Arrixaca, Murcia, Spain. [Rubio-Casadevall,J] Medical Oncology Department, Instituto Catalan Oncologia, Girona, Spain. [De Juan,A] Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain. [Carrasco,JA] Medical Oncology Department, Hospital Alvaro Cunqueiro, Vigo, Spain. [Moura,DS] Instituto de Biomedicina de Sevilla (IBiS; CSIC, US, HUVR), Sevilla, Spain. [Gutiérrez,A] Hematology Department, Hospital Universitario Son Espases, 07010 Palma de Mallorca, Spain.20242024-02-1920212021-02-1420212021-02-14research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttp://hdl.handle.net/20.500.12105/18255reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/182552026-06-12T12:43:37Z |
| score |
15,811543 |